A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

• Status: Terminated
• Trial end date: 2017-08-01

Summary

There is currently no standard treatment for patients with neuro-epithelial (brain) or other solid tumors in another part of the body who do not have adequate suitable autologous hematopoietic progenitor cells available and/or whose disease has relapsed after standard treatment. Allogeneic Hematopoietic Progenitor Cell Transplant may be a consideration for treatment of patients with recurrent chemo-responsive malignant (high grade) neuro-epithelial and other solid tumors or those who do not have suitable autologous hematopoietic progenitor cell availability. The procedure in which your own blood stem cells are transplanted to you is called an autologous (from your own) progenitor cell transplant and when cells from a matched donor are transfused is called an allogeneic progenitor cell transplant. The study is being conducted to evaluate the safety and effectiveness of a combination of drugs followed by an allogeneic hematopoietic progenitor cell transplant (HPCT). This treatment regimen is experimental in that although the individual drugs are commonly used to treat your disease, the specific combination used in this protocol followed by the transplant is experimental.

• Phase: Early Phase 1

Details

• Lead Sponsor: Montefiore Medical Center
• Collaborators: Children's Hospital Los Angeles; Nationwide Children's Hospital
• Treatments: Alemtuzumab; Cyclosporine; Cyclosporins; Etoposide; Etoposide phosphate; Fludarabine; Fludarabine phosphate; Melphalan; Mitogens; Mycophenolate mofetil; Mycophenolic Acid; Polystyrene sulfonic acid; Tacrolimus; Thiotepa